These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 34084235)

  • 1. Factors that affect the Glycemic Control Achieved by Switching to Insulin Degludec/ Aspart in Insulin-Treated Patients with Type 1 and Type 2 Diabetes in a Real-World Setting: a Non-interventional, Retrospective Cohort Study.
    Onder CE; Kuşkonmaz SM; Koc G; Firat S; Omma T; Taskaldiran I; Gokbulut P; Culha C
    Acta Endocrinol (Buchar); 2020; 16(4):443-448. PubMed ID: 34084235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensification of IDegAsp Twice Daily (Adding Insulin Aspart vs. Switching To Basal-Bolus): Exploratory Randomized Trial in Type 2 Diabetes.
    Bebakar WM; Chaykin L; Hersløv ML; Rasmussen S
    Diabetes Ther; 2017 Feb; 8(1):197-205. PubMed ID: 27853981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of Insulin Degludec/Insulin Aspart in the Management of Diabetes Mellitus: Expert Panel Recommendations on Appropriate Practice Patterns.
    Demir T; Turan S; Unluhizarci K; Topaloglu O; Tukek T; Gogas Yavuz D
    Front Endocrinol (Lausanne); 2021; 12():616514. PubMed ID: 33776914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of insulin degludec (IDeg)/insulin Aspart (IAsp) co-formulation therapy twice-daily with free combination of GLP-1 receptor agonist liraglutide plus insulin degludec in Tochigi: IDEAL Trial.
    Aso Y; Takada Y; Tomotsune K; Chiba Y; Matsumura M; Jojima T; Sato M; Fujita N; Kuroda H; Murano S; Usui I
    Int J Clin Pract; 2021 Apr; 75(4):e13734. PubMed ID: 33099848
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of the Novel Degludec/Aspart Insulin Co-formulation in Children and Adolescents with Type 1 Diabetes: A Real-life Experience with One Year of IDegAsp Therapy in Poorly Controlled and Non-compliant Patients.
    Kırkgöz T; Eltan M; Kaygusuz SB; Yavaş Abalı Z; Helvacıoğlu D; Seven Menevşe T; Gürpınar Tosun B; Güran T; Bereket A; Turan S
    J Clin Res Pediatr Endocrinol; 2022 Mar; 14(1):10-16. PubMed ID: 34355879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar glycaemic control with less nocturnal hypoglycaemia in a 38-week trial comparing the IDegAsp co-formulation with insulin glargine U100 and insulin aspart in basal insulin-treated subjects with type 2 diabetes mellitus.
    Philis-Tsimikas A; Astamirova K; Gupta Y; Haggag A; Roula D; Bak BA; Fita EG; Nielsen AM; Demir T
    Diabetes Res Clin Pract; 2019 Jan; 147():157-165. PubMed ID: 30448451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of switching from basal-bolus insulin therapy to twice-daily insulin degludec/insulin aspart co-formulation plus insulin aspart in patients with poorly controlled type 2 diabetes.
    Güneş E; Güneş M
    Eur Rev Med Pharmacol Sci; 2023 Jul; 27(14):6691-6699. PubMed ID: 37522680
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin degludec/insulin aspart administered once daily at any meal, with insulin aspart at other meals versus a standard basal-bolus regimen in patients with type 1 diabetes: a 26-week, phase 3, randomized, open-label, treat-to-target trial.
    Hirsch IB; Bode B; Courreges JP; Dykiel P; Franek E; Hermansen K; King A; Mersebach H; Davies M
    Diabetes Care; 2012 Nov; 35(11):2174-81. PubMed ID: 22933438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
    Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
    Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes: A Real-World, Prospective, Non-interventional Study Across Six Countries.
    Fulcher GR; Akhtar S; Al-Jaser SJ; Medina J; Mohamed M; Nicodemus NA; Olsen AH; Singh KP; Kok A
    Adv Ther; 2022 Aug; 39(8):3735-3748. PubMed ID: 35752730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Experience of our Center in Patients Undergoing Insulin Degludec/ Insulin Aspart Co-formulation Therapy.
    Altay FP; Farzaliyeva A; İyidir ÖT; Bozkuş Y; Kırnap NG; Kut A; Nar A; Tütüncü NB
    Endocr Metab Immune Disord Drug Targets; 2023; 23(6):826-831. PubMed ID: 36424790
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Safety of IDegAsp in a Real-World Korean Population with Type 2 Diabetes Mellitus.
    Kang S; Ahn YB; Oh TK; Lee WY; Chun SW; Bae B; Dahaoui A; Jeong JS; Jung S; Jang HC
    Diabetes Metab J; 2024 Sep; 48(5):929-936. PubMed ID: 38410023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of a fixed combination of insulin degludec/insulin aspart in children and adolescents with type 1 diabetes: A randomized trial.
    Battelino T; Deeb LC; Ekelund M; Kinduryte O; Klingensmith GJ; Kocova M; Kovarenko M; Shehadeh N
    Pediatr Diabetes; 2018 Nov; 19(7):1263-1270. PubMed ID: 30014589
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensification of Insulin Treatment With Insulin Degludec/Aspart in Type 2 Diabetic Patients: A 2-Year Real-World Experience.
    Oner H; Gunhan HG; Gogas Yavuz D
    Front Clin Diabetes Healthc; 2022; 3():783277. PubMed ID: 36992737
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical considerations for use of insulin degludec/insulin aspart in Japanese patients.
    Hirose T; Awata T; Yamamoto Y; Hemmingsen MP
    Expert Opin Biol Ther; 2018 Jan; 18(1):77-85. PubMed ID: 29017373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Initiating or Switching to Insulin Degludec/Insulin Aspart in Adults with Type 2 Diabetes in Malaysia: Results from a Prospective, Non-interventional Real-World Study.
    Mohamed M; Lim SC; Mumtaz M; Uppal S; Mukherjee D; Kassim MSM; Sreedharan S; Doraiswamy AM; Chong KM; Tat LY; Nordin SB; Giek JLH; Hussein Z; Kadir KA; Lau BK; Chan SP
    J ASEAN Fed Endocr Soc; 2023; 38(1):37-44. PubMed ID: 37252419
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical research of insulin glargine U300 basal-bolus therapy and insulin degludec/aspart co-formulation in type 2 diabetes mellitus: A real world experience.
    Kisioglu SV; Demir AS; Tufekci D; Emur Gunay Y; Coskun H; Ucuncu O; Nuhoglu I; Kocak M; Karakullukcu S; Ersoz HO
    Int J Clin Pract; 2021 Sep; 75(9):e14377. PubMed ID: 34003539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IDegAsp (insulin degludec + insulin aspart) for the management of type 2 diabetes: current status.
    Christiansen JS; Home P; Kumar A
    Expert Rev Endocrinol Metab; 2016 Mar; 11(2):103-111. PubMed ID: 30058868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Practical use of insulin degludec/insulin aspart in a multinational setting: beyond the guidelines.
    Mehta R; Chen R; Hirose T; John M; Kok A; Lehmann R; Unnikrishnan AG; Yavuz DG; Fulcher G
    Diabetes Obes Metab; 2020 Nov; 22(11):1961-1975. PubMed ID: 32618405
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Review of Clinical Profile of IDegAsp.
    Unnikrishnan AG; Singh AK; Modi KD; Saboo B; Garcha SC; Rao PV
    J Assoc Physicians India; 2015 May; 63(5 Suppl):15-20. PubMed ID: 26548030
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.